Abstract

Sustained drug delivery strategies have many potential benefits for treating a range of diseases, particularly chronic diseases that require treatment for years. For many chronic ocular diseases, patient adherence to eye drop dosing regimens and the need for frequent intraocular injections are significant barriers to effective disease management. Here, we utilize peptide engineering to impart melanin binding properties to peptide-drug conjugates to act as a sustained-release depot in the eye. We develop a super learning-based methodology to engineer multifunctional peptides that efficiently enter cells, bind to melanin, and have low cytotoxicity. When the lead multifunctional peptide (HR97) is conjugated to brimonidine, an intraocular pressure lowering drug that is prescribed for three times per day topical dosing, intraocular pressure reduction is observed for up to 18 days after a single intracameral injection in rabbits. Further, the cumulative intraocular pressure lowering effect increases ~17-fold compared to free brimonidine injection. Engineered multifunctional peptide-drug conjugates are a promising approach for providing sustained therapeutic delivery in the eye and beyond.

Sustained drug delivery is critical for patient adherence to chronic disease treatments. Here the authors apply machine learning to engineer multifunctional peptides with high melanin binding, high cell-penetration, and low cytotoxicity, enhancing the duration and efficacy of peptide-drug conjugates for sustained ocular delivery.

Details

Title
Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery
Author
Hsueh, Henry T. 1 ; Chou, Renee Ti 2   VIAFID ORCID Logo  ; Rai, Usha 3 ; Liyanage, Wathsala 3 ; Kim, Yoo Chun 3 ; Appell, Matthew B. 4 ; Pejavar, Jahnavi 1 ; Leo, Kirby T. 5   VIAFID ORCID Logo  ; Davison, Charlotte 1 ; Kolodziejski, Patricia 1 ; Mozzer, Ann 3 ; Kwon, HyeYoung 1   VIAFID ORCID Logo  ; Sista, Maanasa 6   VIAFID ORCID Logo  ; Anders, Nicole M. 7 ; Hemingway, Avelina 7 ; Rompicharla, Sri Vishnu Kiran 3 ; Edwards, Malia 8 ; Pitha, Ian 3   VIAFID ORCID Logo  ; Hanes, Justin 9   VIAFID ORCID Logo  ; Cummings, Michael P. 2   VIAFID ORCID Logo  ; Ensign, Laura M. 9   VIAFID ORCID Logo 

 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Chemical & Biomolecular Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 University of Maryland, College Park, Center for Bioinformatics and Computational Biology, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177) 
 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Pharmacology and Molecular Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Biomedical Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Case Western Reserve University, Department of Biomedical Engineering, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA (GRID:grid.280502.d) (ISNI:0000 0000 8741 3625) 
 Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Chemical & Biomolecular Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Pharmacology and Molecular Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Biomedical Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA (GRID:grid.280502.d) (ISNI:0000 0000 8741 3625) 
Pages
2509
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2808439210
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.